Christine Garrett, Ph.D.

Christine (Chris) Garrett is chief strategy officer at Marea Therapeutics. In this role, Chris is responsible for providing strategic guidance and for successfully executing key business initiatives to optimize and support the growth of the company.

Chris brings more than 25 years of industry experience leading high-performing, cross-functional teams at global biopharmaceutical companies to advance the development and life-cycle management of pipeline and approved therapies. Her previous roles have included chief strategy officer of Graphite Bio, where she helped the company successfully execute a reverse merger with Lenz Therapeutics in 2023. Previously, Chris oversaw late development project management for the global R&D organization at Bristol Myers Squibb (BMS), where she significantly contributed to the integration of development programs from Celgene and MyoKardia into the BMS portfolio.
 
Chris has also held senior leadership roles in global R&D projects and portfolio management at Leo Pharma and Celgene. Earlier in her career, she worked at Novartis in various CMC and program leadership roles of increasing responsibility, including as a key contributor to the successful NDA submission, priority review, approval and launch of ENTRESTO™ for HFrEF. Prior to joining the biopharmaceutical industry, she led and executed projects to develop antimicrobial preservatives for a specialty chemicals company.

Chris holds a B.S. in chemistry from the Rochester Institute of Technology and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. She also holds certificates in project management and pharmaceutical business development.